Non-small Cell Lung Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-L

NSCLC Companies working in the Non-small Cell Lung Cancer market are GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Sanofi, IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc

Non-small Cell Lung Cancer Pipeline constitutes 10+ key companies continuously working towards developing 10+ Non-small Cell Lung Cancer treatment therapies, analyzes DelveInsight.

Non-small Cell Lung Cancer Overview:

Non-small-cell lung cancer (NSCLC) refers to any type of epithelial lung cancer except small-cell lung cancer (SCLC) and makes up approximately 85% of all lung cancer cases. There are three main types of NSCLC: a) Adenocarcinoma, which originates in the cells inside the air sacs that produce mucus and other substances, typically in the outer parts of the lungs. It is the most common form of lung cancer among both smokers and nonsmokers, and in people under 45, often growing more slowly than other lung cancers. b) Squamous cell lung cancer, which begins in the cells lining the inner airways of the lungs, accounting for about 25% of lung cancers. c) Large cell (undifferentiated) cancer, which grows and spreads more rapidly, making it harder to treat, and represents about 10% of lung cancers. Treatment for non-small cell adenocarcinoma is primarily based on the cancer's stage, with surgery to remove part or all of the lung typically recommended if the cancer has not spread.

Request for a detailed insights report on Non-small Cell Lung Cancer pipeline insights @ https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Non-small Cell Lung Cancer Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Non-small Cell Lung Cancer Therapeutics Market.

Key Takeaways from the Non-small Cell Lung Cancer Pipeline Report

DelveInsight's Non-small Cell Lung Cancer pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Non-small Cell Lung Cancer treatment.
In September 2024, AbbVie announced that it had submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for the accelerated approval of elotuzumab vedotin (Teliso-V) in adult patients with previously treated, locally advanced or metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) exhibiting c-Met protein overexpression.
In August 2024, the FDA granted Fast Track designation to Deltacel (KB-GDT-01) in combination with low-dose radiation therapy for the potential treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed after two or more prior lines of standard-of-care treatments, including immune checkpoint inhibitors, platinum-based chemotherapy, and targeted therapy.
In July 2024, Nuvalent announced that the first patient had been dosed in the HEROEX-1 Phase Ia/Ib clinical trial of NVL-330, its novel HER2-selective inhibitor.
Key Non-small Cell Lung Cancer companies such as GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Sanofi, IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc, and others are evaluating new drugs for Non-small Cell Lung Cancer to improve the treatment landscape.
Promising Non-small Cell Lung Cancer pipeline therapies in various stages of development include AMG 510, CMP 001, and others.

Non-small Cell Lung Cancer Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Non-small Cell Lung Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-small Cell Lung Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Non-small Cell Lung Cancer market.

Download our free sample page report on Non-small Cell Lung Cancer pipeline insights @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Non-small Cell Lung Cancer Emerging Drugs

AMG 510: Amgen
CMP 001: Cytos Biotechnology

Non-small Cell Lung Cancer Companies

There are over 10 key companies working on developing therapies for Non-Small-Cell Lung Cancer (NSCLC). Among them, Amgen is one of the companies with drug candidates for NSCLC in the mid to advanced stage, specifically Phase I.

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Non-small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Non-small Cell Lung Cancer Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Non-small Cell Lung Cancer Therapies and Key Companies: Non-small Cell Lung Cancer Clinical Trials and advancements @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Non-small Cell Lung Cancer Pipeline Therapeutic Assessment
• Non-small Cell Lung Cancer Assessment by Product Type
• Non-small Cell Lung Cancer By Stage
• Non-small Cell Lung Cancer Assessment by Route of Administration
• Non-small Cell Lung Cancer Assessment by Molecule Type

Download Non-small Cell Lung Cancer Sample report to know in detail about the Non-small Cell Lung Cancer treatment market @ Non-small Cell Lung Cancer Therapeutic Assessment @ https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Non-small Cell Lung Cancer Current Treatment Patterns
4. Non-small Cell Lung Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Non-small Cell Lung Cancer Late-Stage Products (Phase-III)
7. Non-small Cell Lung Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-small Cell Lung Cancer Discontinued Products
13. Non-small Cell Lung Cancer Product Profiles
14. Non-small Cell Lung Cancer Key Companies
15. Non-small Cell Lung Cancer Key Products
16. Dormant and Discontinued Products
17. Non-small Cell Lung Cancer Unmet Needs
18. Non-small Cell Lung Cancer Future Perspectives
19. Non-small Cell Lung Cancer Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Non-small Cell Lung Cancer Pipeline Reports Offerings: https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.